On Tuesday evening, Gilead Sciences announced that it has entered into an agreement with five generic drug manufacturers to manufacture the antiviral drug Remdesivir in 127 countries, except the United States, according to CNBC.
Drug makers Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences will manufacture Remdesivir for distribution in “the facing low and middle income countries, as well as several upper and middle income countries” to health. care barriers in the midst of the coronavirus pandemic. “
“Agreement is ‘royalty free’ until the World Health Organization says the Covid-19 epidemic is no longer a global health crisis or” until a pharmaceutical other than Remdesivir or a vaccine is not approved to treat or prevent Covid-19, as the case may be earlier. “
Despite the positive news for the cure of the coronavirus, fears of the second wave of the virus continue to dominate amid trade tensions between the United States and China, tempering the feeling of risk.
USD / JPY consolidates the rebound above 107.00 while the AUD / USD pair seems to regain 0.6500. However, Asian stocks and S&P 500 futures are trading with moderate losses. US Treasury yields remain heavy, with 10-year yields falling by almost 5%.